| Characteristic . | Patients, n (%) (n = 40) . |
|---|---|
| Age, median years | 51 |
| Range | 30-82 |
| Karnofsky performance status | |
| 100 | 17 (42) |
| 90 | 13 (33) |
| 80 | 8 (20) |
| 70 | 1 (3) |
| HER2 protein expression by IHC* (n = 40) | |
| HER2 3+ | 22 (56) |
| HER2 2+ or “positive” | 17 (44) |
| HER2 expression by FISH† (n = 25) | |
| FISH+ | 12 (48) |
| FISH− | 13 (52) |
| Prior adjuvant therapy | |
| Chemotherapy | 15 (37) |
| Hormone therapy | 16 (40) |
| None | 17 (42) |
| Measurable disease evaluation | |
| Radiological | 37 (93) |
| Physical examination | 3 (7) |
| n of metastatic sites | |
| 1 | 9 (23) |
| 2 | 17 (43) |
| ≥3 | 14 (35) |
| Metastatic sites‡ | |
| Lung/pleura | 17 (42) |
| Lymph node | 13 (32) |
| Soft tissue | 13 (32) |
| Liver | 12 (30) |
| Bone | 10 (25) |
| Characteristic . | Patients, n (%) (n = 40) . |
|---|---|
| Age, median years | 51 |
| Range | 30-82 |
| Karnofsky performance status | |
| 100 | 17 (42) |
| 90 | 13 (33) |
| 80 | 8 (20) |
| 70 | 1 (3) |
| HER2 protein expression by IHC* (n = 40) | |
| HER2 3+ | 22 (56) |
| HER2 2+ or “positive” | 17 (44) |
| HER2 expression by FISH† (n = 25) | |
| FISH+ | 12 (48) |
| FISH− | 13 (52) |
| Prior adjuvant therapy | |
| Chemotherapy | 15 (37) |
| Hormone therapy | 16 (40) |
| None | 17 (42) |
| Measurable disease evaluation | |
| Radiological | 37 (93) |
| Physical examination | 3 (7) |
| n of metastatic sites | |
| 1 | 9 (23) |
| 2 | 17 (43) |
| ≥3 | 14 (35) |
| Metastatic sites‡ | |
| Lung/pleura | 17 (42) |
| Lymph node | 13 (32) |
| Soft tissue | 13 (32) |
| Liver | 12 (30) |
| Bone | 10 (25) |
*Includes determinations on 39 patients.
†Includes determinations on 25 patients.
‡Metastatic sites for patients with measurable disease (n = 3) determined by physical examination included: breast; chest wall; and breast, axilla, and skin.
Abbreviations: HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; FISH = fluorescence in situ hybridization.
| Characteristic . | Patients, n (%) (n = 40) . |
|---|---|
| Age, median years | 51 |
| Range | 30-82 |
| Karnofsky performance status | |
| 100 | 17 (42) |
| 90 | 13 (33) |
| 80 | 8 (20) |
| 70 | 1 (3) |
| HER2 protein expression by IHC* (n = 40) | |
| HER2 3+ | 22 (56) |
| HER2 2+ or “positive” | 17 (44) |
| HER2 expression by FISH† (n = 25) | |
| FISH+ | 12 (48) |
| FISH− | 13 (52) |
| Prior adjuvant therapy | |
| Chemotherapy | 15 (37) |
| Hormone therapy | 16 (40) |
| None | 17 (42) |
| Measurable disease evaluation | |
| Radiological | 37 (93) |
| Physical examination | 3 (7) |
| n of metastatic sites | |
| 1 | 9 (23) |
| 2 | 17 (43) |
| ≥3 | 14 (35) |
| Metastatic sites‡ | |
| Lung/pleura | 17 (42) |
| Lymph node | 13 (32) |
| Soft tissue | 13 (32) |
| Liver | 12 (30) |
| Bone | 10 (25) |
| Characteristic . | Patients, n (%) (n = 40) . |
|---|---|
| Age, median years | 51 |
| Range | 30-82 |
| Karnofsky performance status | |
| 100 | 17 (42) |
| 90 | 13 (33) |
| 80 | 8 (20) |
| 70 | 1 (3) |
| HER2 protein expression by IHC* (n = 40) | |
| HER2 3+ | 22 (56) |
| HER2 2+ or “positive” | 17 (44) |
| HER2 expression by FISH† (n = 25) | |
| FISH+ | 12 (48) |
| FISH− | 13 (52) |
| Prior adjuvant therapy | |
| Chemotherapy | 15 (37) |
| Hormone therapy | 16 (40) |
| None | 17 (42) |
| Measurable disease evaluation | |
| Radiological | 37 (93) |
| Physical examination | 3 (7) |
| n of metastatic sites | |
| 1 | 9 (23) |
| 2 | 17 (43) |
| ≥3 | 14 (35) |
| Metastatic sites‡ | |
| Lung/pleura | 17 (42) |
| Lymph node | 13 (32) |
| Soft tissue | 13 (32) |
| Liver | 12 (30) |
| Bone | 10 (25) |
*Includes determinations on 39 patients.
†Includes determinations on 25 patients.
‡Metastatic sites for patients with measurable disease (n = 3) determined by physical examination included: breast; chest wall; and breast, axilla, and skin.
Abbreviations: HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; FISH = fluorescence in situ hybridization.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
